Every year, the Preceptorship course brings together relevant haematologists in the study of Acute Lymphoblastic Leukaemia (ALL), with the aim of updating and sharing the most up-to-date information on the biology, diagnosis and treatment of this disease. Organized by the Group Leader of the Acute Lymphoblastic Leukaemia group, Dr. Josep-Maria Ribera, with the support of Incyte, the 3rd edition was held last 10 and 11 November, once again at the Josep Carreras Leukaemia Research Institute (IJC).
This year's edition was open to biologists and physicians from Germany, Belgium, Finland, Italy, Slovenia and Spain, who were able to learn about the latest developments in ALL, including those to be presented at the next congress of the American Society of Hematology. The scientific programme was prepared by Dr. Ribera and included talks by high-level speakers on the biology of ALL, standard treatments and novel therapies, such as immunotherapy, cellular or personalized therapy.
Dr. Ribera is pleased with the outcome of the meeting, which he believes shows "the current expertise in the study of ALL, which we must not forget is the spearhead of research in haematological malignancies and cancer in general". Dr. Ribera is also grateful for the support of the Josep Carreras Institute and the Catalan Institute of Oncology in the organization of the course and highlights the great work carried out by the Acute Lymphoblastic Leukaemia group of IJC in research on this disease.